Hybribio (300639.SZ) exhibited live at the 75th ADLM (former AACC) Annual Scientific Meeting & Clinical Lab Expo, July 25-27, at Anaheim Convention Center, California, USA. This event attracted 958 exhibitors and over 70,000 attendees worldwide from different areas of clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of progressing laboratory science.
At the booth No.1482, Hybribio (300639.SZ) featured cervical cancer HPV diagnostic solutions, which include Hybribio 14 High-risk HPV with 16/18 Genotyping Real-time PCR Kit, 21 HPV GenoArray Diagnostic Kit, 37 HPV GenoArray Diagnostic Kit, 13 High-risk HPV Real-time PCR Kit, 23 HPV Genotyping Real-time PCR Kit, 14 High-Risk HPV E6/E7 mRNA Real-time PCR Kit (PCR with Fluorescent Probe), and SOX1 and PAX1 Methylation Real-time PCR Kit. Hybribio presented its successful experience in cervical cancer prevention and control in China to global attendees, aiming to unite experts in different aspects (clinical laboratories, hospitals, research institutes, enterprises, etc.) to promote the global elimination of cervical cancer. Moreover, all HPV detection kits manufactured by Hybribio are CE-certified and have been exported to more than 20 countries around the world.
Hybribio at ADLM 2023 Clinical Lab Expo
Being the top HPV DNA test manufacturer in China, Hybribio (300639.SZ) not only has the biggest Chinese market share (over 40%) of HPV testing kits but also contributes greatly to the movement of eliminating cervical cancer. In the past two decades, Hybribio has taken up 40 % of national breast-cervical cancer screening projects and provided more than 50 million HPV DNA tests for females in China (2003-2023). Furthermore, Hybribio established the China HPV database with the Ministry of Health P. R. China in 2009, monitoring the long-term evolution of Human Papillomavirus infection and cervical cancer in China.
The booth highlighted 14 High-risk HPV with 16/18 Genotyping Real-time PCR Kit, which successfully obtained the first clinical screening license approved in China, with a high sensitivity and specificity of 93.6% and 88.46%, respectively. The negative predictive value using this kit with a 3-year follow-up is 99.84% which means that this kit is explicitly suitable for cervical cancer primary screening, co-screening with pap smear and ASC-US triage. Moreover, Hybribio HPV testing reagents have achieved a 100% coincident rate in the WHO HPV external quality assessment for seven consecutive times from 2011 to 2022.
For laboratory automated instrument, the fully Automated Sample Preparation Liquid System (HB-IEX96A) integrates functions including de-capping and re-capping, barcode scanning, tube loading, pipetting, nucleic acid extraction and PCR plate liquid transferring, which is able to achieve a one-step workflow and enhance laboratory efficiency by reducing human errors. The in-booth demonstration of this instrument drew many visitors’ attention, attributed to its wide applicability, powerful functions and excellent design. With this fully Automated Sample Preparation Liquid System (HB-IEX96A), it could alleviate laboratory labor burden and improve testing efficiency significantly for a large-scale screening project.
The year 2023 is the 20th anniversary of Hybribio Biotech. Hybribio has been adhering to its original aspiration of taking care of maternity and child health in the past two decades. In Molecular diagnostics, Hybribio has developed a series of nucleic acid diagnostics kits for reproductive health infections, neonatal and prenatal genetic diseases, respiratory tract infections and cancer markers. By 2023, one billion people have benefited from using Hybribio’s products and services. Meanwhile, Hybribio is constantly expanding its product line in different areas. Apart from molecular diagnostic assays and automated instruments, Hybribio also develops a variety of laboratory consumables, including pipette tips, PCR consumables, deep-well place, tip comb and sample tubes.
Hybribio (300639.SZ) is going to attend MEDICA 2023 at Dusseldorf, Germany, 13-16 November 2023. Hybribio is looking forward to meeting you in person at MEDICA 2023, where Hybribio will feature more cutting-edge diagnostics solutions and high-throughput automated instruments.
Founded in 2003, Hybribio (300639.SZ) is a leading nucleic acid test supplier and manufacturer who specializes in in-vitro diagnostic products with a fully integrated one-step operation chain from R&D, manufacturing, and sales & marketing to after-sales technical support services. Hybribio provides products including, but not limited to, HPV testing, reproductive health, genetic diseases, methylation, respiratory tract infection, pharmacogenetics and instrumentation.
For more information, please visit: www.hybribio.com